Compare Glenmark Pharma with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs CIPLA - Comparison Results

GLENMARK PHARMA     Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA CIPLA GLENMARK PHARMA/
CIPLA
 
P/E (TTM) x 12.9 22.5 57.3% View Chart
P/BV x 1.8 2.5 74.6% View Chart
Dividend Yield % 0.5 0.7 83.9%  

Financials

 GLENMARK PHARMA   CIPLA
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-19
CIPLA
Mar-19
GLENMARK PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs712678 105.0%   
Low Rs484484 100.0%   
Sales per share (Unadj.) Rs349.6198.2 176.4%  
Earnings per share (Unadj.) Rs32.818.5 177.0%  
Cash flow per share (Unadj.) Rs44.335.0 126.7%  
Dividends per share (Unadj.) Rs2.003.00 66.7%  
Dividend yield (eoy) %0.30.5 64.8%  
Book value per share (Unadj.) Rs198.6186.3 106.6%  
Shares outstanding (eoy) m282.17805.70 35.0%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.72.9 58.3%   
Avg P/E ratio x18.231.4 58.1%  
P/CF ratio (eoy) x13.516.6 81.2%  
Price / Book Value ratio x3.03.1 96.5%  
Dividend payout %6.116.2 37.7%   
Avg Mkt Cap Rs m168,625468,031 36.0%   
No. of employees `00012.022.6 53.2%   
Total wages/salary Rs m20,56128,565 72.0%   
Avg. sales/employee Rs Th8,196.07,053.1 116.2%   
Avg. wages/employee Rs Th1,708.11,261.5 135.4%   
Avg. net profit/employee Rs Th768.5659.1 116.6%   
INCOME DATA
Net Sales Rs m98,655159,710 61.8%  
Other income Rs m2,0814,766 43.7%   
Total revenues Rs m100,736164,475 61.2%   
Gross profit Rs m15,85830,973 51.2%  
Depreciation Rs m3,25913,263 24.6%   
Interest Rs m3,3461,684 198.7%   
Profit before tax Rs m11,33520,791 54.5%   
Minority Interest Rs m0-172 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1,6720-   
Tax Rs m3,7565,695 66.0%   
Profit after tax Rs m9,25014,924 62.0%  
Gross profit margin %16.119.4 82.9%  
Effective tax rate %33.127.4 121.0%   
Net profit margin %9.49.3 100.3%  
BALANCE SHEET DATA
Current assets Rs m66,968124,266 53.9%   
Current liabilities Rs m40,21137,715 106.6%   
Net working cap to sales %27.154.2 50.0%  
Current ratio x1.73.3 50.5%  
Inventory Days Days8391 92.0%  
Debtors Days Days8195 85.6%  
Net fixed assets Rs m33,322105,190 31.7%   
Share capital Rs m2821,611 17.5%   
"Free" reserves Rs m55,770148,511 37.6%   
Net worth Rs m56,052150,123 37.3%   
Long term debt Rs m35,73838,301 93.3%   
Total assets Rs m132,888239,633 55.5%  
Interest coverage x4.413.3 32.9%   
Debt to equity ratio x0.60.3 249.9%  
Sales to assets ratio x0.70.7 111.4%   
Return on assets %9.56.9 136.8%  
Return on equity %16.59.9 166.0%  
Return on capital %17.811.8 150.5%  
Exports to sales %034.7 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA55,419 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m62,99857,410 109.7%   
Fx outflow Rs m22,85919,041 120.0%   
Net fx Rs m40,14038,368 104.6%   
CASH FLOW
From Operations Rs m13,24216,911 78.3%  
From Investments Rs m-6,990-16,687 41.9%  
From Financial Activity Rs m-7,387-3,487 211.8%  
Net Cashflow Rs m-2,971-3,451 86.1%  

Share Holding

Indian Promoters % 48.3 16.0 301.9%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 6.9 12.2 56.6%  
FIIs % 34.4 23.7 145.1%  
ADR/GDR % 0.0 1.1 -  
Free float % 10.5 26.2 40.1%  
Shareholders   56,727 161,166 35.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   DISHMAN PHARMA  ELDER PHARMA  SUVEN LIFESCIENCES  DR. DATSONS LABS  CADILA HEALTHCARE  

Compare GLENMARK PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 72 Points Lower; Capital Goods and Auto Stocks Witness Selling(Closing)

India share markets witnessed selling pressure during closing hours and ended their day marginally lower.

Related Views on News

SANOFI INDIA Surges by 5%; BSE HEALTHCARE Index Up 1.4% (Market Updates)

Nov 18, 2019 | Updated on Nov 18, 2019

SANOFI INDIA share price has surged by 5% and its current market price is Rs 6,820. The BSE HEALTHCARE is up by 1.4%. The top gainers in the BSE HEALTHCARE Index are SANOFI INDIA (up 5.0%) and GLENMARK PHARMA (up 20.6%). The top losers are FORTIS HEALTHCARE (down 0.1%) and CIPLA (down 0.3%).

WOCKHARDT Surges by 11%; BSE HEALTHCARE Index Up 1.1% (Market Updates)

Nov 18, 2019 | Updated on Nov 18, 2019

WOCKHARDT share price has surged by 11% and its current market price is Rs 306. The BSE HEALTHCARE is up by 1.1%. The top gainers in the BSE HEALTHCARE Index are WOCKHARDT (up 11.4%) and GLENMARK PHARMA (up 15.4%). The top losers are LAURUS LABS LTD and BLISS GVS PHARMA .

PARAG MILK FOODS LTD Surges by 10%; BSE 500 Index Down 0.1% (Market Updates)

Nov 18, 2019 | Updated on Nov 18, 2019

PARAG MILK FOODS LTD share price has surged by 10% and its current market price is Rs 140. The BSE 500 is down by 0.1%. The top gainers in the BSE 500 Index are PARAG MILK FOODS LTD (up 10.3%) and GLENMARK PHARMA (up 14.9%). The top losers are J.B.CHEMICALS and G.E.SHIPPING .

WOCKHARDT Surges by 11%; BSE HEALTHCARE Index Up 1.0% (Market Updates)

Nov 18, 2019 | Updated on Nov 18, 2019

WOCKHARDT share price has surged by 11% and its current market price is Rs 306. The BSE HEALTHCARE is up by 1.0%. The top gainers in the BSE HEALTHCARE Index are WOCKHARDT (up 11.3%) and GLENMARK PHARMA (up 14.7%). The top losers are LAURUS LABS LTD and BLISS GVS PHARMA .

SANOFI INDIA Surges by 5%; BSE HEALTHCARE Index Up 1.5% (Market Updates)

Nov 18, 2019 | Updated on Nov 18, 2019

SANOFI INDIA share price has surged by 5% and its current market price is Rs 6,820. The BSE HEALTHCARE is up by 1.5%. The top gainers in the BSE HEALTHCARE Index are SANOFI INDIA (up 5.2%) and GLENMARK PHARMA (up 17.2%). The top losers are PIRAMAL ENTERPRISES (down 0.2%) and LAURUS LABS LTD (down 0.4%).

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Nov 18, 2019 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - PROCTER & GAMBLE HEALTH COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS